Disease-Focused Discovery

PureTech established the underlying programs and platforms that resulted in a substantial pipeline comprised of 24 products and product candidates that are being advanced both internally and through PureTech's Founded Entities, including two products that have been cleared by the FDA.

View our corporate deck.

PureTech's Components of Value

Wholly Owned Pipeline

Our programs
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
LYT-100
Deupirfenidone
Lymphatic flow disorders, incl. lymphedema
Initiation of POC study in 2020

1

Lymphatic flow disorders, incl. lymphedema

~1M

Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-100
Deupirfenidone
COVID-19 post-recovery respiratory complications
Initiation of POC study in Q3 2020

1

COVID-19 post-recovery respiratory complications


Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).
LYT-100
Deupirfenidone
Other fibrotic & inflammatory disorders

1

Other fibrotic & inflammatory disorders

~130K (IPF or uILD)


Product candidate for a range of conditions involving fibrosis, inflammation and impaired lymphatic flow, including lymphedema, idiopathic pulmonary fibrosis (IPF), interstitial pneumonias, unclassifiable interstitial lung disease (uILD) and other interstitial lung disease (ILD), radiation-induced fibrosis and focal segmental glomerulosclerosis (FSGS).

LYT-200
Anti-Galectin-9 MAb
Solid tumors
IND and initiation of Ph1a/1b study in 2020

Preclinical

Solid tumors

57K/year (Pancreatic cancer)
146K/year (CRC)
8K/year (Cholangiocarcinoma)


LYT-200 is an investigational, fully human, IgG4 monoclonal antibody (mAb) that is designed to target galectin-9, a protein that regulates immunosuppression and is prominently expressed in hard-to-treat cancers, such as colorectal cancer, or CRC, cholangiocarcinoma, pancreatic cancer and others.

LYT-210
Anti-Delta-1 MAb
Solid tumors

Preclinical

Solid tumors

57K/year (Pancreatic Cancer)
146K/year (CRC)
8K/year (Cholangiocarcinoma)


LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

LYT-210
Anti-Delta-1 MAb
GI autoimmunity

Preclinical

GI autoimmunity

57K/year (Pancreatic Cancer)
146K/year (CRC)
8K/year (Cholangiocarcinoma)


LYT-210 is an investigational, fully human IgG1 monoclonal antibody (mAb) directed against the delta-1 (γδ1) chain of T cells bearing γδ1 T cell receptors (TCRs) for antibody-dependent cell-mediated cytotoxicity and antibody-dependent cellular phagocytosis (ADCP).

Lymphatic Targeting Chemistry Platform
Orphan & other
neurological indications

A synthetic lymphatic targeting chemistry platform being developed to employ the body’s natural lipid absorption and transport process to orally administer drugs via the lymphatic system by (1) targeting the mesenteric lymph nodes and (2) bypassing first-pass metabolism.

Milk Exosome Platform

A milk exosome-based technology being developed to enable oral administration of macromolecule therapeutic payloads, including antisense oligonucleotides, short interfering RNA, messenger RNA (mRNA), peptides and nanoparticles that are otherwise administered exclusively by injection.

Meningeal Lymphatics Platform

A platform that aims to correct lymphatic dysfunction in the brain to potentially improve outcomes for a range of neurodegenerative and neuroinflammatory conditions that are not currently effectively treated, such as Alzheimer’s disease and Parkinson’s disease.

Phase completedPhase in progress

Founded Entities

$666.8m


Secured for Founded Entities in 2019, 93.4% from Third Parties1

Controlling Interest or Right to Receive Royalties

Developing therapies for people with severe neuropsychiatric disorders and pain

18.1% Equity plus Royalties
PHASE 3 READY2
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
KarXT

Schizophrenia

~2.7M U.S.

Phase 3 Ready2
Dementia-related psychosis
~8.4M U.S.
Phase 1
Pain
Phase 1

Targeting the GI system locally to treat the genesis of chronic disease

22.0% Equity plus Royalties
FDA CLEARED,
EUROPEAN CE MARK GRANTED
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
Plenity®*+

Weight management

~150M U.S. (Overweight and obesity)

FDA Cleared,
European CE Mark Granted
Product Candidate:
GS100*++

Adolescent weight management

~13.7M U.S.

Phase 2 Ready**
Product Candidate:
GS500*++

Chronic idiopathic constipation

~35M U.S.

Phase 3 Ready**
Product Candidate:
Gelesis200*++

Weight management in type 2 diabetes (T2D)/prediabetes

~30M U.S. (T2D)
~84M U.S. (Prediabetes)

Phase 2
Product Candidate:
GS300*++

Non-alcoholic steatohepatitis/Non-alcoholic fatty liver disease

~80-100M U.S.

Phase 2 Ready**
Product Candidate:
GS400*++
Inflammatory bowel disease
~3M U.S.
Preclinical

A regenerative platform for hair growth

78.3% Equity plus Royalties
PHASE 3 READY
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
FOL-004

Androgenetic alopecia

~90M U.S.

Phase 3 Ready
Product Candidate:
FOL-005

Skin rejuvenation

Phase 2
Targeting devastating GI disease
78.6% Equity
PRECLINICAL
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
ALV-306
Pouchitis and distal colitis
~70K-135K U.S. (Pouchitis)
~225K U.S. (Distal colitis)
Preclinical
Product Candidate:
ALV-304
Inflammatory bowel disease
~3M U.S.
Preclinical
Product Candidate:
ALV-107
Interstitial cystitis/Bladder pain syndrome
~4-12M U.S.
Preclinical
Founded by scientific leaders in the fields of immunology and the microbiome
53.3% Equity
PHASE 2
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
VE303

High-risk Clostridioides difficile

~100-120K/year U.S.

Phase 2
Product Candidate:
VE416

Food allergy

~2.5M U.S. (Peanut allergy)

Phase 1/2
Product Candidate:
VE202

Inflammatory bowel disease

~3M U.S.

Phase 1
Product Candidate:
VE800

Solid tumors

>46K/year U.S. (Advanced & metastatic MSS CRC)
>11K/year U.S. (Gastric cancers)
>9K/year U.S. (Melanoma)

Phase 1
Unlocking voice as a vital sign and meaningful predictor of health
45.9% Equity
PHASE 1
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
Sonde

Depression detection

~17M U.S.

Phase 1
Engineering hydrogels to enable oral delivery of biologics
72.9% Equity
PRECLINICAL
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
ENT-100

Oral delivery of biologics, vaccines and other drugs

Preclinical

Equity Interest Only

Digital therapeutics for people living with cognitive impairment
34.4% Equity
FDA CLEARED,
EUROPEAN CE MARK GRANTED
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
EndeavorRx™ (AKL-T01)

Pediatric ADHD

~6.4M U.S. (Pediatric ADHD)

FDA Cleared,
European CE Mark Granted

Parkinson’s/MCI

Phase 1 (Feasibility)

Traumatic brain injury

Phase 1 (Feasibility)
Product Candidate:
AKL-T02

Pediatric autism

~1.5M U.S.

Phase 2 (POC)
Product Candidate:
AKL-T03

Multiple sclerosis

~900K U.S.

Phase 2 (POC)

Major depressive disorder

~17M U.S.

Pivotal Study Ready***
Product Candidate:
AKL-T04

Major depressive disorder

~17M U.S.

Preclinical
Product Candidate:
AKL-X01

ADHD caregiver app

Clinical Trials
Engineered hematopoietic stem cells that unleash the potential of targeted therapies
11.8% Equity
PRECLINICAL
Product Candidate
Initial Indication
Patient Population
Stage of Development
Product Candidate:
VOR33
Acute myeloid leukemia
~60K U.S.
Preclinical

1. Funding figure includes private equity financings, public offerings or grant awards. Funding figure excludes upfront payments and future milestone considerations received in conjunction with partnerships and collaborations such as those with Roche, Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly.

2. Following the completion of a successful End-of-Phase 2 meeting with the U.S. FDA, Karuna remains on track to initiate the Phase 3 program by the end of 2020.

Note: This figure represents the stage of development for each Founded Entity’s most advanced product candidate. While PureTech maintains ownership of equity interests in its Founded Entities, the Company does not, in all cases, maintain control over these entities (by virtue of (i) majority voting control and (ii) the right to elect representation to the entities’ board of directors) or direct the management and development efforts for these entities. Consequently, not all such entities are consolidated in the financial statements. Where PureTech maintains control, the entity is referred to as a Controlled Founded Entity in this report and is consolidated in the financial statements. Where PureTech does not maintain control, the entity is referred to as a Non-Controlled Founded Entity in this report and is not consolidated in the financial statements. As of 31 December 2019, Controlled Founded Entities include Alivio Therapeutics, Inc., Follica, Incorporated, Entrega, Inc., Vedanta Biosciences, Inc. and Sonde Health, Inc., and Non-Controlled Founded Entities include Akili Interactive Labs, Inc., Gelesis, Inc., Karuna Therapeutics, Inc., Vor Biopharma Inc. and, for all periods prior to December 18, 2019, resTORbio, Inc. Relevant ownership interests for Founded Entities were calculated on a diluted basis (as opposed to a voting basis) as of 31 December 2019 (with the exception of Gelesis ownership which is as of 1 April 2020 and Vor ownership which is as of 30 June 2020), including outstanding shares, options and warrants, but excluding unallocated shares authorized to be issued pursuant to equity incentive plans. Ownership of Vor is based on the assumption that all future tranches of the most recent financing round are funded. Karuna ownership is calculated on an outstanding voting share basis as of 26 May 2020.

+ Important Safety Information: Plenity is contraindicated in patients who are pregnant or are allergic to cellulose, citric acid, sodium stearyl fumarate, gelatine, or titanium dioxide. Plenity may alter the absorption of medications. Read Sections 6 and 8.3 of the Instructions for Use carefully. Avoid use in patients with the following conditions: esophageal anatomic anomalies, including webs, diverticuli, and rings; suspected strictures (such as patients with Crohn’s disease); or complications from prior gastrointestinal (GI) surgery that could affect GI transit and motility. Use with caution in patients with active GI conditions such as gastro-esophageal reflux disease (GERD), ulcers or heartburn. The overall incidence of adverse events (AEs) in the Plenity group was no different than the placebo group. The most common side effects were diarrhea, distended abdomen, infrequent bowel movements, and flatulence. For the safe and proper use of Plenity, U.S. Instructions for Use or the EU Instructions for Use. 

* These product candidates are regulated as devices and their development has been approximately equated to phases of clinical development.

** Contingent on FDA review of the research plan.

*** Future clinical research plans and priorities in process.

Cash at PureTech Parent Level

$321.5m


PureTech Level Pro-forma Cash Reserves3

$120.6m


PureTech Level Cash Reserves as of December 31, 20194

$45m


Cash from KRTX Equity Sale on May 25, 20205

3. PureTech Level Pro-forma Cash Reserves is an alternative performance measure (APM) which includes the PureTech Level Cash Reserves of $120.6 million and the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares. PureTech Pro-forma Cash Reserves is therefore considered to be more representative of the Corporate’s cash available for the year 2020 and beyond to advance product candidates within the full breadth of its operations.

4. PureTech Level Cash Reserves represent cash balances and short-term investments held at PureTech Health LLC, PureTech Management, Inc., PureTech Health PLC, PureTech Securities Corporation of $112.0 million for the year ended 2019 and the internal pipeline of $8.6 million for the year ended 2019, all of which are wholly-owned entities of PureTech, excluding cash balances and short-term investments of Controlled Founded Entities. The balance excludes the $200.9 million in proceeds from the 22 January 2020 sale of 2.1 million Karuna common shares.

5. 44.5 million in proceeds from the 22 May 2020 sale of 555.5 thousand Karuna common shares.

The BIG Idea - Moving medicine forward at PureTech

Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out
Collaborative drug discovery based on proprietary biological insights
Rapid & cost-efficient prioritization & validation
Develop internally, partner or spin-out

Relationships with multiple major pharma companies or their investment arms